• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
Percent of COVID-19 hospitalizations decreasing

Percent of COVID-19 hospitalizations decreasing

by Truveta Research | Jan 28, 2022 | Research, Research Insights

Just last week marked the two-year anniversary of the first case of COVID-19 in the United States, discovered by our health system member Providence. It’s hard to believe that it’s been two years, and just this past month we’ve experienced the highest number of daily...
Partnering to improve data quality and health equity

Partnering to improve data quality and health equity

by Terry Myerson, CEO | Jan 18, 2022 | News

Truveta and Lexis Nexis Risk Solutions partner to create the most complete, highest quality U.S. public health data platform    2022 is off to a rough start with this Omicron variant. I continue to be in awe of the healthcare community who continue to work...
Introducing the Truveta platform and new COVID-19 insights

Introducing the Truveta platform and new COVID-19 insights

by Terry Myerson, CEO | Nov 9, 2021 | News

 Today I am excited to introduce the Truveta Platform for health systems and life science companies, share new insights about COVID-19 from the Truveta Platform, and welcome three new large regional health systems – Ochsner Health, Saint Luke’s Health System...
The first insights from the Truveta platform: COVID-19

The first insights from the Truveta platform: COVID-19

by Truveta staff | Nov 9, 2021 | Research, Research Insights

Today is a special day for us at Truveta. In just under two weeks, our team was able to ask and answer an important medical question using one of the largest comprehensive real-time datasets of fully vaccinated Americans. This inaugural custom study is an illustration...
Next Entries »

Share this


Recent posts

  • Real-world survival outcomes for CRT and CCM therapies align with landmark trials
  • Understanding the potential impact of the upcoming ACIP vote on thimerosal-containing influenza vaccines
  • Biosimilar use is on the rise – but 1 in 8 patients return to Humira

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice